Systemic neoadjuvant therapy has long been administered with the objective to improve operability of locally advanced breast cancer. In the neoadjuvant setting it is possible to employ all targeted and non-targeted therapies as wasshown in a number of clinical trials, and thereby positively influence future perspective of the patients.